Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1261-1270 |
| Number of pages | 10 |
| Journal | AIDS (London, England) |
| Volume | 31 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Jun 2017 |
Keywords
- atazanavir
- chronic renal impairment
- estimated glomerular filtration rate
- HIV
- reversibility
- tenofovir
- abacavir
- atazanavir plus ritonavir
- Human immunodeficiency virus proteinase inhibitor
- indinavir
- lopinavir plus ritonavir
- ritonavir
- anti human immunodeficiency virus agent
- adult
- age
- aged
- Article
- cohort analysis
- diabetes mellitus
- disease course
- human
- Human immunodeficiency virus infected patient
- Human immunodeficiency virus infection
- hypertension
- kidney dysfunction
- major clinical study
- male
- observational study
- outcome assessment
- priority journal
- prospective study
- chronic kidney failure
- complication
- female
- glomerulus filtration rate
- highly active antiretroviral therapy
- middle aged
- pathology
- procedures
- prognosis
- Adult
- Aged
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Female
- Glomerular Filtration Rate
- HIV Infections
- Humans
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Renal Insufficiency, Chronic
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. / ; Torres, Ferran.
In: AIDS (London, England), Vol. 31, No. 9, 06.2017, p. 1261-1270.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals
AU - Ryom, L.
AU - Mocroft, A.
AU - Kirk, O.
AU - Reiss, P.
AU - Ross, M.
AU - Smith, C.
AU - Moranne, O.
AU - Morlat, P.
AU - Fux, C.A.
AU - Sabin, C.
AU - Phillips, A.
AU - Law, M.
AU - Lundgren, J.D.
AU - Powderly, B.
AU - Shortman, N.
AU - Moecklinghoff, C.
AU - Reilly, G.
AU - Franquet, X.
AU - Hatleberg, C.I.
AU - Sabin, C.A.
AU - Kamara, D.
AU - Bojesen, A.
AU - Nielsen, J.
AU - Matthews, C.
AU - Raben, D.
AU - Brandt, R.S.
AU - Rickenbach, M.
AU - Fanti, I.
AU - Krum, E.
AU - Hillebregt, M.
AU - Geffard, S.
AU - Mourabi, J.
AU - Sundström, A.
AU - Delforge, M.
AU - Fontas, E.
AU - McManus, H.
AU - Wright, S.
AU - Kjær, J.
AU - Kristensen, D.
AU - Sjøl, A.
AU - Meidahl, P.
AU - Helweg-Larsen, J.
AU - Iversen, J.S.
AU - Smit, C.
AU - Kamara, D.A.
AU - Weber, R.
AU - Pradier, C.
AU - Friis-Møller, N.
AU - Kowalska, J.
AU - D'Arminio Monforte, A.
AU - Torres, Ferran
N1 - Cited By :16 Export Date: 17 February 2022 CODEN: AIDSE Correspondence Address: Ryom, L.; Rigshospitalet, Section 2100, Finsencentret, Blegdamsvej 9, Denmark; email: lene.ryom.nielsen@regionh.dk Chemicals/CAS: abacavir, 136470-78-5, 188062-50-2; atazanavir, 198904-31-3; indinavir, 150378-17-9, 157810-81-6, 180683-37-8; ritonavir, 155213-67-5; tenofovir, 147127-19-3, 147127-20-6; Anti-HIV Agents Funding details: QLK2-2000-00773 Funding details: LSHP-CT-2006-018632 Funding details: CT94-1637, CT97-2713 Funding details: National Institutes of Health, NIH, 5U01AI042170-10, 5U01AI046362-03 Funding details: U.S. Food and Drug Administration, FDA Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01-AI069907 Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer Funding details: GlaxoSmithKline, GSK Funding details: Roche Funding details: Styrelsen för Internationellt Utvecklingssamarbete, Sida Funding details: Janssen Research and Development, JRD Funding details: Gilead Sciences Funding details: AbbVie, 148522 Funding details: Boehringer Ingelheim Funding details: Janssen Pharmaceuticals, DNRF126 Funding details: Merck Sharp and Dohme, MSD Funding details: Seventh Framework Programme, FP7, 260694 Funding details: British Microcirculation Society, BMS Funding details: European Commission, EC Funding details: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNSF, 108787 Funding details: Danmarks Grundforskningsfond, DNRF Funding details: University of New South Wales, UNSW Funding details: Ministerie van Volksgezondheid, Welzijn en Sport, VWS Funding details: Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS Funding details: Fundación Emilio Soldevilla para la Investigación y el Desarrollo en Economía de la Empresa, FESIDE, FIPSE 3171/00 Funding details: Beijing Innovation Center for Future Chip, ICFC Funding details: INCLIVA Instituto de Investigación Sanitaria, FIS 99/0887 Funding text 1: The work was supported by the HAART Oversight Committee (HAART-OC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc. and Janssen Pharmaceuticals. Supported also by a grant (grant number DNRF126) from the Danish National Research Foundation (CHIP & PERSIMUNE); by a grant from the Dutch Ministry of Health, Welfare and Sport (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les hépatites virales (ANRS, Action Coordonnée no.7, Cohortes) to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) (grant number U01-AI069907) and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim Roche; Pfizer; GlaxoSmithKline and Janssen Pharmaceuticals. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales. By grants from the Fondo de Investigación Sanitaria (grant number FIS 99/0887) and Fundación para la Investigación y la Prevención del SIDA en Espanã (grant number FIPSE 3171/00), to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grants numbers 5U01AI042170-10 and 5U01AI046362-03), to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by grants from the BIOMED 1 (grant number CT94-1637) and BIOMED 2 (grant number CT97-2713) programs and the 5th framework program (grant number QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord no. 260694) programmes of the European Commission and unrestricted grants by Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC, [the participation of centers from Switzerland is supported by The Swiss National Science Foundation (grant 108787)] to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithK-line, Pfizer, Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and by a grant from the Swiss National Science Foundation (grant no. 148522) to the Swiss HIV Cohort Study (SHCS). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. Funding text 2: [28], which was supported by the EuroSIDA study [6]. Other PI-related urolithiasis are relatively rare, although asymptomatic crystalluria may be more prevalent and have, to date, not been assessed in safety trials. Funding text 3: The work was supported by the HAART Oversight Committee (HAART-OC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc. and Janssen Pharmaceuticals. Supported also by a grant (grant number DNRF126) from the Danish National Research Foundation (CHIP & PERSIMUNE); by a grant from the Dutch Ministry of Health, Welfare and Sport (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les h?patites virales (ANRS, Action Coordonn?e no.7, Cohortes) to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) (grant number U01-AI069907) and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim Roche; Pfizer; GlaxoSmithKline and Janssen Pharmaceuticals. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales. By grants from the Fondo de Investigaci?n Sanitaria (grant number FIS 99/0887) and Fundaci?n para la Investigaci?n y la Prevenci?n del SIDA en Espan?(grant number FIPSE 3171/00), to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grants numbers 5U01AI042170-10 and 5U01AI046362-03), to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by grants from the BIOMED 1 (grant number CT94-1637) and BIOMED 2 (grant number CT97-2713) programs and the 5th framework program (grant number QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord no. 260694) programmes of the European Commission and unrestricted grants by Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC, [the participation of centers from Switzerland is supported by The Swiss National Science Foundation (grant 108787)] to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and by a grant from the Swiss National Science Foundation (grant no. 148522) to the Swiss HIV Cohort Study (SHCS). References: Wever, K., Van Agtmael, M.A., Carr, A., Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men (2010) J Acquir Immune Defic Syndr, 55, pp. 78-81; Malik, A., Abraham, P., Malik, N., Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature (2005) J Infect, 51, pp. E61-65; Kapitsinou, P.P., Ansari, N., Acute renal failure in an AIDS patient on tenofovir: A case report (2008) J Med Case Rep, 2, p. 94; Jose, S., Hamzah, L., Campbell, L.J., Hill, T., Fisher, M., Leen, C., Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure (2014) J Infect Dis, 210, pp. 363-373; Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients (2010) AIDS, 24, pp. 1667-1678; Flandre, P., Pugliese, P., Cuzin, L., Bagnis, C.I., Tack, I., Cabie, A., Risk factors of chronic kidney disease in HIV-infected patients (2011) Clin J Am Soc Nephrol, 6, pp. 1700-1707; Ryom, L., Mocroft, A., Kirk, O., Worm, S.W., Kamara, D.A., Reiss, P., Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study (2013) J Infect Dis, 207, pp. 1359-1369; Scherzer, R., Estrella, M., Li, Y., Choi, A.I., Deeks, S.G., Grunfeld, C., Association of tenofovir exposure with kidney disease risk in HIV infection (2012) AIDS, 26, pp. 867-875; Nolin, T.D., Himmelfarb, J., Mechanisms of drug-induced nephrotoxicity (2010) Handb Exp Pharmacol, 196, pp. 111-130; Berdichevski, R.H., Luis, L.B., Crestana, L., Manfro, R.C., Amphotericin B-related nephrotoxicity in low-risk patients (2006) Braz J Infect Dis, 10, pp. 94-99; Jao, J., Wyatt, C.M., Antiretroviral medications: Adverse effects on the kidney (2010) Adv Chronic Kidney Dis, 17, pp. 72-82; Yao, X., Panichpisal, K., Kurtzman, N., Nugent, K., Cisplatin nephrotoxicity: A review (2007) Am J Med Sci, 334, pp. 115-124; Fabrizii, V., Thalhammer, F., Horl, W.H., Aminoglycoside-induced nephrotoxicity (1997) Wien Klin Wochenschr, 109, pp. 830-835; Yoshino, M., Yagura, H., Kushida, H., Yonemoto, H., Bando, H., Ogawa, Y., Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation (2012) J Infect Chemother, 18, pp. 169-174; Izzedine, H., Hulot, J.S., Vittecoq, D., Gallant, J.E., Staszewski, S., Launay-Vacher, V., Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study (2005) Nephrol Dial Transplant, 20, pp. 743-746; Campbell, L.J., Hamzah, L., Post, F.A., Is tenofovir-related renal toxicity incompletely reversible? (2011) J Acquir Immune Defic Syndr, 56, p. e95. , author reply e95-96; Nelson, M.R., Katlama, C., Montaner, J.S., Cooper, D.A., Gazzard, B., Clotet, B., The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years (2007) AIDS, 21, pp. 1273-1281; Eriksen, B.O., Ingebretsen, O.C., The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age (2006) Kidney Int, 69, pp. 375-382; Friis-Moller, N., Sabin, C.A., Weber, R., D'Arminio Monforte, A., El-Sadr, W.M., Reiss, P., Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16, pp. 31-41; Mosteller, R.D., Simplified calculation of body-surface area (1987) N Engl J Med, 317, p. 1098; Vrouenraets, S.M., Fux, C.A., Wit, F.W., Garcia, E.F., Brinkman, K., Hoek, F.J., A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function (2012) Clin Nephrol, 77, pp. 311-320; Chan-Tack, K.M., Truffa, M.M., Struble, K.A., Birnkrant, D.B., Atazanavir-adverse event reporting system (2007) AIDS, 21, pp. 1215-1218; Turin, T.C., Coresh, J., Tonelli, M., Stevens, P.E., De Jong, P.E., Farmer, C.K., One-year change in kidney function is associated with an increased mortality risk (2012) Am J Nephrol, 36, pp. 41-49; Mocroft, A., Lundgren, J.D., Ross, M., Law, M., Reiss, P., Kirk, O., Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study (2015) PLoS Med, 12, p. e1001809; Scherzer, R., Gandhi, M., Estrella, M.M., Tien, P.C., Deeks, S.G., Grunfeld, C., A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans (2014) AIDS, 28, pp. 1289-1295
PY - 2017/6
Y1 - 2017/6
N2 - Objectives: The objectives of this analysis were to investigate predictors of progression, stabilization or improvement in estimated glomerular filtration rate (eGFR) after development of chronic renal impairment (CRI) in HIV-positive individuals. Design: Prospective observational study. Methods: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study participants progressing to CRI defined as confirmed, at least 3 months apart, and eGFR 70 ml/min per 1.73 m2 or less were included in the analysis. The median of all eGFRs measured 24-36 months post-CRI was compared with the median eGFR defining CRI, and changes were grouped into improvement (>+10 ml/min per 1.73 m2), stabilization (-10 to +10 ml/min per 1.73 m2) and progression (<-10 ml/min per 1.73 m2). Adjusted polynomial regression models assessed odds of better eGFR outcomes after CRI, assuming that eGFR improvement is better than stabilization which in turn is better than progression. Results: Of 2006 individuals developing CRI, 21% subsequently improved eGFR, 67% stabilized and 12% progressed. Individuals remaining on tenofovir (TDF) or atazanavir boosted with ritonavir (ATV/r) 24 months post-CRI had worse eGFR outcomes compared with those unexposed [TDF: 0.47 (0.35-0.63) and ATV/r: 0.63 (0.48-0.82)]. Individuals off TDF for 12-24 months [0.75 (0.50-1.13)] or off ATV/r for more than 12 months [1.17 (0.87-1.57)] had similar eGFR outcomes as those unexposed to these antiretrovirals. Older age, hypertension, later date of CRI and diabetes were associated with worse eGFR outcomes. Conclusion: Current TDF and ATV/r use after a diagnosis of CRI was associated with worse eGFR outcomes. In contrast, TDF and ATV/r discontinuation lead to similar longer term eGFR outcomes as in those unexposed, suggesting that these drug-associated eGFR declines may be halted or reversed after their cessation. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
AB - Objectives: The objectives of this analysis were to investigate predictors of progression, stabilization or improvement in estimated glomerular filtration rate (eGFR) after development of chronic renal impairment (CRI) in HIV-positive individuals. Design: Prospective observational study. Methods: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study participants progressing to CRI defined as confirmed, at least 3 months apart, and eGFR 70 ml/min per 1.73 m2 or less were included in the analysis. The median of all eGFRs measured 24-36 months post-CRI was compared with the median eGFR defining CRI, and changes were grouped into improvement (>+10 ml/min per 1.73 m2), stabilization (-10 to +10 ml/min per 1.73 m2) and progression (<-10 ml/min per 1.73 m2). Adjusted polynomial regression models assessed odds of better eGFR outcomes after CRI, assuming that eGFR improvement is better than stabilization which in turn is better than progression. Results: Of 2006 individuals developing CRI, 21% subsequently improved eGFR, 67% stabilized and 12% progressed. Individuals remaining on tenofovir (TDF) or atazanavir boosted with ritonavir (ATV/r) 24 months post-CRI had worse eGFR outcomes compared with those unexposed [TDF: 0.47 (0.35-0.63) and ATV/r: 0.63 (0.48-0.82)]. Individuals off TDF for 12-24 months [0.75 (0.50-1.13)] or off ATV/r for more than 12 months [1.17 (0.87-1.57)] had similar eGFR outcomes as those unexposed to these antiretrovirals. Older age, hypertension, later date of CRI and diabetes were associated with worse eGFR outcomes. Conclusion: Current TDF and ATV/r use after a diagnosis of CRI was associated with worse eGFR outcomes. In contrast, TDF and ATV/r discontinuation lead to similar longer term eGFR outcomes as in those unexposed, suggesting that these drug-associated eGFR declines may be halted or reversed after their cessation. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
KW - atazanavir
KW - chronic renal impairment
KW - estimated glomerular filtration rate
KW - HIV
KW - reversibility
KW - tenofovir
KW - abacavir
KW - atazanavir plus ritonavir
KW - Human immunodeficiency virus proteinase inhibitor
KW - indinavir
KW - lopinavir plus ritonavir
KW - ritonavir
KW - anti human immunodeficiency virus agent
KW - adult
KW - age
KW - aged
KW - Article
KW - cohort analysis
KW - diabetes mellitus
KW - disease course
KW - human
KW - Human immunodeficiency virus infected patient
KW - Human immunodeficiency virus infection
KW - hypertension
KW - kidney dysfunction
KW - major clinical study
KW - male
KW - observational study
KW - outcome assessment
KW - priority journal
KW - prospective study
KW - chronic kidney failure
KW - complication
KW - female
KW - glomerulus filtration rate
KW - highly active antiretroviral therapy
KW - middle aged
KW - pathology
KW - procedures
KW - prognosis
KW - Adult
KW - Aged
KW - Anti-HIV Agents
KW - Antiretroviral Therapy, Highly Active
KW - Female
KW - Glomerular Filtration Rate
KW - HIV Infections
KW - Humans
KW - Male
KW - Middle Aged
KW - Prognosis
KW - Prospective Studies
KW - Renal Insufficiency, Chronic
UR - http://www.ncbi.nlm.nih.gov/pubmed/28492392
U2 - 10.1097/QAD.0000000000001464
DO - 10.1097/QAD.0000000000001464
M3 - Article
C2 - 28492392
VL - 31
SP - 1261
EP - 1270
IS - 9
ER -